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Abstract  
 
Background 
Monitoring response and resistance to kinase inhibitors is essential to 
precision cancer medicine, and is usually investigated by molecular profiling 
of a tissue biopsy obtained at progression. However, tumor heterogeneity and 
tissue sampling bias limit the effectiveness of this strategy. In addition, tissue 
biopsies are not always feasible and are associated with risks due to the 
invasiveness of the procedure. To overcome these limitations, blood-based 
liquid biopsy analysis has proven effective to non-invasively follow tumor’s 
clonal evolution.  
 
Patients and methods 
We exploited urine cell-free, trans-renal DNA (tr-DNA) and matched plasma 
circulating tumor DNA (ctDNA) to monitor a metastatic colorectal cancer 
patient carrying a CAD-ALK translocation during treatment with an ALK 
inhibitor.  
 
Results 
Using a custom Next Generation Sequencing (NGS) panel we identified the 
genomic CAD-ALK rearrangement and a TP53 mutation in plasma ctDNA. 
Sensitive assays were developed to detect both alterations in urine tr-DNA. 
The dynamics of the CAD-ALK rearrangement in plasma and urine were 
concordant and paralleled patient’s clinical course. Detection of CAD-ALK 
gene fusion in urine tr-DNA anticipated radiological confirmation of disease 
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progression. Analysis of plasma ctDNA identified ALK kinase mutations that 
emerged during treatment with the ALK inhibitor entrectinib. 
 
Conclusion 
We find that urine-based genetic testing allows tracing of tumor-specific 
oncogenic rearrangements. This strategy could be effectively applied to non-
invasively monitor tumor evolution during therapy. The same approach could 
be exploited to monitor minimal residual disease after surgery with curative 
intent in patients whose tumors carry gene fusions. The latter could be 
implemented without the need of patient hospitalization since urine tr-DNA 
can be self-collected, is stable over time and can be shipped at specified time-
points to central labs for testing. 
 
 
Key words:  
colorectal cancer; liquid biopsy; circulating DNA; trans-renal DNA; ALK 
translocation; ALK inhibitor  
 
 
Key message:  
A CAD-ALK rearrangement was tracked in urine trans-renal DNA (tr-DNA) 
and plasma circulating tumor DNA (ctDNA) of a metastatic colorectal cancer 
patient receiving treatment with an ALK inhibitor. The detection of oncogenic 
gene fusions in urine tr-DNA is feasible and its dynamics during treatment 
parallel changes observed in plasma ctDNA. 
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Introduction 
 
Anaplastic lymphoma kinase (ALK) receptor is a tyrosine kinase encoded by 
the ALK gene. Gene fusion is the most frequent molecular alteration occurring 
in this gene across different tumor types including non-small cell lung cancer 
(NSCLC), leukemia, anaplastic large cell lymphoma (ALCL), inflammatory 
myofibroblastic tumor (IMT), and colorectal cancers (CRC) [1, 2]. ALK gene 
rearrangements lead to constitutive receptor dimerization and activation, 
resulting in uncontrolled tumor cell proliferation and activation of downstream 
MAPK and AKT pathways [3].   
Recent studies have shown that plasma circulating tumor DNA (ctDNA) can 
be used to effectively monitor response and emergence of resistance during 
the course of treatment with targeted agents [4-6]. While liquid biopsies are 
most commonly applied to plasma-derived ctDNA, recent analyses have 
focused on DNA isolated from other body fluids, such as cerebrospinal fluid, 
saliva and urine [7-9]. It is known that a portion of blood ctDNA is cleared by 
the kidney barrier filtration and is excreted in urine in the form of small 
fragments (less than 100 bp) [10]. The applicability and clinical utility of liquid 
biopsies based on urine trans-renal DNA (tr-DNA) has not been extensively 
explored. Technical difficulties in detecting the highly fragmented and low 
abundant tumor-specific DNA in urine have limited progress in this field [10].  
 
We reasoned that PCR-based assays designed to detect genetic 
rearrangements such as the CAD-ALK translocation could be used to assess 
the validity of urine as a source of tumor-specific genetic information. A 
metastatic colorectal (mCRC) patient whose tumor displayed a CAD-ALK 
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translocation showed a remarkable response during treatment with 
entrectinib, a potent and selective panTRK/ROS1/ALK inhibitor [11]. Here we 
exploited urine tr-DNA and matched blood ctDNA of this patient to monitor the 
CAD-ALK oncogenic rearrangement during ALK blockade.  
 
 
Results 
 
Acquired resistance to ALK inhibition in a CRC patient 
A molecular screen identified a 53-years-old mCRC patient with brain, 
thoracic lymph nodes and liver metastases carrying a CAD-ALK gene fusion 
[11]. After several rounds of standard treatments including surgery on the 
primary tumor (right hemicolectomy), external beam radiation therapy to the 
central nervous system (CNS) metastases (brain and cerebellum) and 
thoracic lymph nodes, and two lines of chemotherapy (both with oxaliplatin, 5-
fluorouracil/leucovorin, and bevacizumab), administered before and after the 
radiation therapy, the patient displayed disease progression in the liver 
metastasis. 
 
The patient’s tumor harbored a rearrangement involving CAD exon 35 to ALK 
exon 20. We and others have previously reported that CRC cell models 
harboring ALK translocations are sensitive to ALK pharmacological inhibition 
[1, 12]. 
Based on this evidence, the patient was enrolled in the phase I clinical trial 
(EudraCT Number 2012-000148-88) of the panTRK/ROS1/ALK kinase 
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inhibitor entrectinib, a first-in-class drug currently undergoing clinical testing 
[13, 14].  
The patient received entrectinib on a 400 mg/m-2 po qd (by mouth daily) 
dosing schedule. CT scans (Computed Tomography) evaluations were 
planned as per protocol every 8 weeks. In case of PR/CR, confirmation of 
response by another CT scan was mandatory after 4 weeks. At baseline in 
March 2015, a CT scan revealed stable and asymptomatic CNS disease 
(brain and cerebellum), and right and left liver lobe involvement. The 
treatment induced remarkable tumor shrinkage and was well tolerated, 
leading to a rapid partial response with a decrease in the sum of the target 
lesions by 38%, confirmed by a subsequent CT scan in July 2015 (Figure 1a). 
Brain and cerebellum metastases remained stable during the duration of the 
treatment. After 18 weeks of clinical response, drug resistance occurred, as 
evaluated by a CT scan in late August 2015, and the patient died in 
September 2015 due to progression of liver disease and hepatic failure.  
 
Detection of CAD-ALK gene fusion in plasma ctDNA 
To identify the CAD-ALK fusion genomic breakpoint, we analyzed plasma 
ctDNA through liquid biopsy [15], an approach we previously optimized to 
detect and monitor drug resistance in patients treated with targeted agents [4, 
16]. 
 
ctDNA isolated from a plasma sample collected prior to treatment initiation 
(baseline) was subjected to molecular profiling using an NGS panel (IRCC-
Fusion panel) we purposely designed to interrogate 52 common cancer gene 
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rearrangements (Supplementary Table 1a) and 14 frequently mutated genes 
in cancer patients (Supplementary Table 1b). Profiling of the pre-treatment 
specimen unveiled a TP53 p.R248W mutation and detected the CAD-ALK 
gene fusion (Supplementary Table 2a), that was also present in the tumor 
tissue of the same individual [11]. 
 
The ALK rearrangement is present in urine tr-DNA and mirrors patient's 
response 
Urine (90-110 ml of first morning void) and blood samples were longitudinally 
collected during treatment with the ALK inhibitor. Urine tr-DNA was isolated as 
described in the methods section and fragments’ size distribution was 
evaluated using a 2100 Bioanalyzer (Supplementary Figure 1). The amount of 
tr-DNA extracted from the baseline urine sample (March 2015) was not 
sufficient to perform the analyses and was excluded (Supplementary Figure 
1a). 
 
Urine tr-DNA differs from plasma ctDNA in that there is a large amount of 
contaminating normal DNA shed by cells of the urinary tract in urine and 
consisting of high-molecular weight fragments. A standard Droplet Digital 
PCR (ddPCR) [17] approach failed to detect the rearrangement in tr-DNA. We 
reasoned that highly sensitive assays would be needed to detect the CAD-
ALK rearrangement and the TP53 mutation in tr-DNA. We designed several 
end-point PCR assays to detect the CAD-ALK gene fusion. We found that a 
51 bp assay was optimally suited to detect the translocation in tr-DNA (Figure 
1b and Supplementary Figure 2a). Using the amplicon-based assay, the 
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presence of the gene fusion was detectable in all urine and plasma time-
points analyzed (Figure 1b and Supplementary Figure 2). The tr-DNA from an 
unrelated CRC patient served as a negative control. CAD-ALK levels 
increased in August 2015 when the patient showed clinical progression 
(Figure 1b). Of note, the CAD-ALK gene fusion was apparent in urine tr-DNA 
before radiological confirmation of progressive disease (Figure 1b and 
Supplementary Figure 2a). To validate the specificity of the assay we 
performed TOPO TA cloning of the PCR products followed by Sanger 
sequencing. The results confirmed the presence of the genomic 
rearrangement (Supplementary Figure 3). 
 
To detect the TP53 p.R248W variant, as an alternative marker of tumor 
burden and response to treatment in urine tr-DNA, peptide nucleic acid (PNA) 
probes were designed to specifically suppress amplification of wild-type (WT) 
fragments. TP53 mutated alleles were detected in all time-points 
(Supplementary Figure 4).   
 
 
Emergence of secondary ALK mutations in plasma ctDNA during 
entrectinib treatment  
To uncover molecular alterations associated with emergence of secondary 
resistance to entrectinib treatment, plasma ctDNA obtained at clinical relapse 
was investigated with the NGS-based IRCC-TARGET panel we previously 
described [4]. ctDNA profiling at progression to entrectinib confirmed the 
presence of the TP53 p.R248W mutation already detected in the baseline 
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plasma sample by the IRCC-Fusion panel NGS analysis (data not shown). 
Additionally, the analysis revealed five ALK point mutations in exons 21, 23 
and 24 (p.F1174C, p.F1174L C>G and T>C, p.G1128A and p.F1245V) in the 
kinase domain of the protein, which were not detected in ctDNA obtained prior 
to entrectinib treatment (Supplementary Table 2b).  
 
To longitudinally monitor mutant ALK alleles in plasma samples collected over 
the course of treatment, ddPCR assays were designed for individual 
mutations. To monitor overall disease, the TP53 p.R248W founder mutation, 
as identified by NGS (Supplementary Table 2a), was also followed by ddPCR 
analysis in plasma ctDNA (Figure 2). Longitudinal ddPCR analysis of plasma 
ctDNA revealed that ALK mutations were initially absent (or present at very 
low levels) and emerged as early as 8 weeks upon initiation of treatment with 
entrectinib (Figure 2 and Supplementary Table 3). ALK mutation frequencies 
continued to increase in plasma ctDNA until clinical progression was 
radiologically confirmed (20 weeks after initiation of treatment).  
 
 
Discussion 
 
Mechanisms of resistance to targeted therapies are usually investigated by 
molecular profiling of a tissue biopsy obtained at progression. However, tumor 
heterogeneity and biases associated with tissue sampling limit the 
effectiveness of this strategy. In addition, tissue biopsies are not always 
feasible and are associated with risks due to the invasiveness of the 
procedure.  
 10 
 
To address these issues we and others exploited plasma ctDNA to genotype 
solid tumors non-invasively and monitor clonal evolution during treatment with 
targeted agents [4, 6, 19-22]. However, blood draws are not exactly non-
invasive and phlebotomy requires the involvement of a health professional. 
Furthermore, the blood volume is limited, and its collection can be impaired by 
health conditions and other reasons; this affects the frequency of collection, 
limiting patient’s monitoring in real time. 
 
In principle, these limitations can be overcome using circulating tr-DNA [23, 
24]. Urine can be collected at home and there are no quantitative or timing 
limitations to sample collection. This may be particularly valuable in some 
clinical settings, for example monitoring minimal residual disease (MRD) after 
surgery with curative intent. In this situation, one can envision the patient 
collecting urine at home over several days (weeks) followed by centralized 
analyses of trans-renal DNA aimed at identification of cancer specific 
alterations to determine MRD. We also note that recent evidence indicates 
that urine tr-DNA analysis can reach remarkable sensitivity when using 
appropriate sample volumes [7, 25]. 
 
Only a limited number of studies have exploited DNA extracted from urine for 
the molecular characterization of cancer patients [7, 26-29]. Concordance 
among somatic mutations detected in matched tumor tissue, plasma, and 
urine has been reported [7, 30]. These reports include KRAS mutations in 
CRC, BRAF mutations in histiocytic disorders and EGFR mutations in NSCLC 
[7, 27]. Several causes have limited the use of tr-DNA as a source of tumor-
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specific genomic information. For example, it is currently unclear what fraction 
of cancer patients carries tumor-derived DNA fragments in urine. Another 
limitation to the use of tr-DNA is that tumor DNA represents a very low fraction 
of the total tr-DNA, and therefore detection assays must be highly sensitive. 
We reasoned that oncogenic rearrangements (gene fusions) would be 
uniquely suited for urine-based assays since PCR reactions spanning 
somatically rearranged loci are not influenced by the presence of wild-type 
DNA that is found in large amounts in tr-DNA.    
 
To provide proof of concept that this approach is feasible, we studied urine tr-
DNA and matched plasma ctDNA of a patient with a CAD-ALK rearranged 
metastatic colorectal cancer who received the ALK kinase inhibitor, 
entrectinib. Our findings suggest that detection of gene fusions in urine tr-DNA 
is feasible and that its dynamics during treatment with a targeted agent 
parallel changes observed in plasma ctDNA.  
 
Sequencing plasma ctDNA further revealed that during entrectinib treatment 
several ALK mutations (p.F1174C, p.F1174L, p.F1245V and p.G1128A) 
emerged. These variants were reported in both familial and sporadic 
neuroblastoma [31-34] and were also functionally linked to secondary 
resistance to other ALK inhibitors in NSCLC, as well as in neuroblastoma [32, 
35-37]. p.F1174 is one of the most common hotspot mutations in exon 23, 
which is located at the end of the kinase domain C-helix [3], with the 
occurrence of p.F1174L and the p.F1174C alterations being the most and 
least frequent, respectively (37% and 4% among ALK mutant 
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neuroblastomas) [31].  The p.G1128A mutation (exon 21) was found in 
neuroblastoma, and it is located in the glycine-rich P loop, generating a gain 
of function kinase [3, 38]. Although the mechanism of activation is not clear, 
this mutation presumably alters interaction of the kinase domain with ATP 
increasing phosphate transfer. The ALK p.F1245V mutation in exon 24, 
previously observed in sporadic neuroblastoma [3], is located in the tyrosine 
kinase domain, and corresponds to the L833 residue of EGFR, a mutation 
which is associated with gefitinib resistance in lung cancer [32].  Mutations 
occurring at codons 1174 and 1245 have a strong effect on ALK receptor 
auto-phosphorylation due to the destabilization of ALK’s auto inhibitory 
interaction and promotion of tyrosine kinase domain activation [38]. Of note, 
p.F1174L mutation that we detected at resistance to entrectinib is sensitive to 
second-generation ALK inhibitors such as alectinib and TAE684 [32, 39]. 
Similarly, ASP3026 displays activity against the activating ALK mutants 
F1174L and R1275Q and against the crizotinib-resistant gatekeeper mutation 
L1196M [40]. Our data suggest that additional lines of therapy based on 
already available ALK inhibitors could be administered concomitantly to 
prevent or overcome the emergence of resistance.  
In summary, we find that urine-based genetic testing allows the tracing of 
tumor-specific oncogenic rearrangements. This strategy could be effectively 
applied to non-invasively monitor tumor evolution during therapy. The same 
approach could also be employed to monitor minimal residual disease after 
surgery with curative intent in patients whose tumors carry gene fusions. The 
latter do not require patient hospitalization since urine DNA can be self-
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collected, is stable over time and can be shipped to central labs for testing 
[23].  
This study provides proof of concept that trans-renal DNA can be effective in 
monitoring tumor evolution. The approach should now be validated in large 
number of patients.  
This study assessed a limited number of genetic variants in tr-DNA, in the 
future NGS approaches will likely provide a more comprehensive landscape 
of trans-renal DNA. While the analysis of trans-renal tumor DNA are presently 
complex and limited by sensitivity, advances on DNA sequencing 
technologies will likely overcome current limitations. 
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Material and Methods 
 
Patient’s case report   
The patient received treatment with entrectinib 400 mg/m2 2 po qd within the 
ALKA-372-001 phase I study (EudraCT Number: 2012-000148-88) for which 
she provided informed consent. Objective tumor response was measured by 
computed tomography (CT) using the Response Evaluation Criteria in Solid 
Tumors (RECIST version 1.1) [41]. Patient’s urine and plasma samples were 
obtained through study protocols approved by the Ethical Committee at 
Ospedale Niguarda, Milan, Italy.  
 
Plasma and urine Samples Collection  
At least 10 mL of whole blood were collected by blood draw using EDTA as 
anticoagulant. Plasma was separated within 5 hours through 2 different 
centrifugation steps (the first at room temperature for 10 minutes at 1,600 × g 
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and the second at 3,000 × g for the same time and temperature), obtaining up 
to 3 mL of plasma. Plasma was stored at -80°C until ctDNA extraction. 
Urine samples, between 50-110 mL, were collected in the clinic into 120- mL 
cups, supplemented with preservative, and stored at or below -70°C.  
 
ctDNA and tr-DNA isolation from plasma and urine  
ctDNA was extracted from plasma using the QIAamp Circulating Nucleic Acid 
Kit (Qiagen) according to the manufacturer’s instructions.  
For urinary DNA extraction, urine was concentrated to 4 mL using Vivacell 
100 concentrators (Sartorius Corp) and incubated with 700 µl of Q-sepharose 
Fast Flow quaternary ammonium resin (GE Healthcare). Tubes were spun to 
collect sepharose and bound DNA. The pellet was re-suspended in a buffer 
containing guanidinium hydrochloride and isopropanol, and the eluted DNA 
was collected as a flow-through using polypropylene chromatography 
columns (Bio-Rad). The DNA was further purified using Qia-Quick columns 
(Qiagen). tr-DNA fragment size distribution was assessed using the 2100 
Bioanalyzer High-Sensitivity DNA assay kit (Agilent Technologies) according 
to the manufacturer’s instructions. 
 
Droplet Digital PCR analysis 
Isolated circulating free DNA was amplified using ddPCR™ Supermix for 
Probes (Bio-Rad) with ALK p.F1174C, p.F1174L (C>G and T>C), p.G1128A, 
p.F1245V and TP53 p.R248W assays (custom designed probes). ddPCR was 
then performed according to the manufacturer’s protocol and the results were 
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reported as percentage or fractional abundance of mutant DNA alleles to total 
(mutant plus wild type) DNA alleles.  
8–10 µl of DNA template was added to 10 µl of ddPCR Supermix for Probes 
(Bio-Rad) and 2 µl of the primer and probe mixture. Droplets were generated 
using Auto-DG where the reaction mix was added together with Droplet 
Generation Oil for Probes (Bio-Rad). Droplets were then transferred to a 96-
well plate (Eppendorf) and then thermal cycled with the following conditions: 5 
minutes at 95°C, 40 cycles of 94°C for 30s, 55°C for 1 minute followed by 
98°C for 10 minutes (Ramp Rate 2°C/sec). Droplets were analyzed with the 
QX200 Droplet Reader (Bio-Rad) for fluorescent measurement of FAM and 
HEX probes. Gating was performed based on positive and negative controls, 
and mutant populations were identified. The ddPCR data were analyzed with 
QuantaSoft analysis software (Bio-Rad) to obtain fractional abundance of the 
mutated alleles in the wild-type or normal background. The quantification of 
the target molecule was presented as number of total copies (mutant plus 
WT) per sample in each reaction. The number of positive and negative 
droplets is used to calculate the concentration of the target and reference 
DNA sequences and their Poisson-based 95% confidence intervals, as 
previously shown [42]. ddPCR analysis of normal control DNA (from cell lines) 
and no DNA template controls were always included. Samples with too low 
positive events were repeated at least twice in independent experiments to 
validate the obtained results. 
 
End-point PCR analysis 
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End-point PCR was performed as follows: ctDNA and tr-DNA with 0.05 U of 
platinum Taq DNA polymerase (Invitrogen), 1X platinum buffer (Invitrogen), 1 
mM dNTPs (Invitrogen), 1.5 mM MgCl2 (Invitrogen), 1 µM of each primer was 
amplified using the following cycling conditions: 1 cycle of 98 °C for 2 min; 3 
cycles of 98 °C for 10 s, 68 °C for 15 s, 72 °C for 15 s; 3 cycles of 98 °C for 10 
s, 65 °C for 15 s, 72 °C for 15 s; 3 cycles of 98 °C for 10 s, 63 °C for 15 s, 72 
°C for 15 s; 41 cycles of 98 °C for 10 s, 57 °C for 15 s, 72 °C for 15 s. Specific 
ultra-short primer pairs (51 bp amplicon) were used. Primer sequences are 
available upon request. 4% Agarose gel electrophoresis was subsequently 
performed with E-Gel® 1 Kb Plus DNA Ladder (Thermo Fisher Scientific). 
Bands of interest were quantified by Image J software (NIH Image, NIH 
Bethesda, USA). Calculation was done by subtracting the background 
intensity (calculated by measuring the intensity of an area which does not 
have any bands in chemiluminescent film) from intensity of the band of 
interest. 
 
TOPO TA cloning and Sanger Sequencing 
CAD-ALK specific amplicon obtained by end-point PCR performed on gDNA 
obtained from the PDX (positive control), plasma ctDNA and urine tr-DNA 
were cloned in TOP10 competent cells using the TOPO® TA Cloning® Kit for 
Sequencing (Life Technologies) according to the manufacturer’s protocol. 
Samples were then subjected to automated sequencing by ABI PRISM 3730 
(Applied Biosystems) with M13 reverse primer. 
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Peptide nucleic acids (PNA) assays 
Peptide nucleic acid (PNA)-mediated clamped PCR was performed as 
follows: tr-DNA with 0.05 U of platinum Taq DNA polymerase (Invitrogen), 1X 
platinum buffer (Invitrogen), 1 mM dNTPs (Invitrogen), 1.5 mM MgCl2 
(Invitrogen), 1 µM of each primer and 35 nM of custom designed TP53 codon 
248 PNA (NH2-TGAACCGGAGGCCCATCC-CONH2) was amplified with the 
following conditions: 5 minutes at 95°C, 40 cycles of 94°C for 30 s, 85°C for 
30 s, 55°C for 1 minute followed by 98°C for 10 minutes (Ramp Rate 
2°C/sec). Bands were quantified as per End-Point PCR procedure above. 
 
IRCC-Fusion and IRCC-TARGET Next Generation Sequencing panels  
IRCC-Fusion panel was designed selecting the most recurrent seven kinase 
fusions in cancer. For all of them the most frequent rearrangement partners 
were identified.  Capture probes were designed exploiting the tool available 
online (https://designstudio.illumina.com), covering the exon and intron of the 
upstream 5’ and the downstream 3’ partner (Supplementary table 1a). 
The panel also covers: hot-spot mutations previously associated to resistance 
to EGFR blockade in CRC (KRAS, NRAS, BRAF, PIK3CA, MAP2K1, EGFR); 
promoter of the epidermal growth factor receptor (EGFR) ligands; all coding 
exons of four genes known to be involved in CRC tumorigenesis (PTEN, 
TP53, APC, CTNNB1) (Supplementary table 1b).  
Libraries were prepared with Nextera Rapid Capture Custom Enrichment Kit 
(Illumina Inc., San Diego, CA, USA), according to the manufacturer’s protocol. 
Libraries preparation was performed using up to 150ng of plasma ctDNA with 
NEBNext® Ultra™ DNA Library Prep Kit for Illumina® (New England BioLabs 
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Inc., Ipswich MA), with optimized protocol. ctDNA was then used as template 
for indexing PCR which allows the introduction of unique sample barcodes. 
DNA fragments’ size distribution was assessed using the 2100 Bioanalyzer 
with the High Sensitivity DNA assay kit (Agilent Technologies, Santa Clara, 
CA). Equal amount of DNA libraries were pooled and subjected to targeted 
panel hybridization capture. Libraries were then sequenced on the Illumina 
MiSeq sequencer (Illumina Inc., San Diego, CA, USA). Full description of 
IRCC-TARGET panel can be found in [5]. 
 
Bioinformatic Analysis 
To detect the CAD-ALK rearrangement, a mix of BWA [44] and BLAT [45] was 
used. Reads were first aligned with BWA to the hg19 human reference 
genome. Afterwards, reads that were not perfectly aligned by BWA, potentially 
harboring translocations, were further processed using BLAT (tileSize=11, 
stepSize=5). The resulting PSL alignment was post-processed with a custom 
built script to detect alignments supporting translocations events. Gene fusion 
calling was performed according to the following criteria: each fusion partner 
must have at least 25 nucleotides mapped to the respective part of the read; 
the fusion partners must map to two different genes; each fusion breakpoint 
must be supported by at least 10 reads. 
To detect somatic variation, FastQ files generated by Illumina MiSeq were 
mapped to the human reference (assembly hg19) using BWA-mem algorithm 
[44]. Sequences were then processed to remove all bases in the read with a 
Phred quality score less than 20. PCR duplicates were removed using the 
SAMtools package [46]. Somatic variations were called according to 
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previously published methods [5]. A mutational analysis with IRCC-TARGET 
panel was performed comparing the pre- and post- treatment samples; with 
Mini-Fusion panel, the human genome (hg19) was used as reference to call 
somatic variations. Mutations were annotated printing out gene information, 
number of normal and mutated reads, allelic frequencies, variation effect and 
the association of each hit with the corresponding number of occurrences in 
the COSMIC database [47]. 
 
 
 
Figure legends 
 
 
Figure 1  
Monitoring CAD-ALK rearrangement in patient’s plasma ctDNA and 
urine tr-DNA (a) CT scans of a mCRC patient harboring a CAD-ALK 
rearrangement were recorded at baseline (March 2015), at the time of partial 
response (July 2015) and upon disease progression to the 
panTRK/ROS1/ALK inhibitor entrectinib (August 2015). (b) Longitudinal 
analysis of plasma ctDNA collected at different time-points throughout the 
treatment. Black and red bars: absolute CAD-ALK fragments intensity 
measured by end-point PCR performed on plasma and urine samples 
respectively.  
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Figure 2 
Monitoring tumor evolution in patient’s plasma ctDNA through ddPCR 
analysis 
Longitudinal analysis of plasma ctDNA collected at different time-points 
throughout the treatment. Black line: TP53 mutated alleles (%); grey, purple, 
green, red and blue lines: ALK mutated alleles (%). PR: partial response; PD: 
progressive disease 
 
 
Supplementary Figure 1 
Bioanalyzer High-Sensitivity DNA chip electropherograms 
(a-f) panels show tr-DNA fragments size distribution assessed using the 2100 
Agilent Bioanalyzer High-Sensitivity DNA assay kit.  
 
Supplementary Figure 2 
Top panels: 4% agarose gel electrophoresis showing CAD-ALK specific 
amplicons from urine tr-DNA (a) and plasma ctDNA (b) obtained by end-point 
PCR. 
Bottom panels: peaks area obtained by measuring gel bands intensity of 
CAD-ALK gene fusion alleles observed in urine tr-DNA (a) and plasma ctDNA 
(b) using Image J software.  
 
Supplementary Figure 3 
Sanger sequencing electropherograms showing the CAD-ALK genomic 
break-point region obtained through TOPO TA cloning of the end-point PCR 
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amplicon obtained from patient’s tumor tissue (patient-derived xenograft: 
PDX) used as positive control and from plasma ctDNA and urine tr-DNA 
(August 28th time-point). 
 
Supplementary Figure 4 
Tracking TP53 mutation in urine tr-DNA 
(a) 4% agarose gel electrophoresis showing mutant TP53 p.R248W specific 
amplicons from urine tr-DNA obtained by PNA-clamp PCR. (b) Absolute 
quantification of TP53 p.R248W bands intensity in urine tr-DNA exploiting 
PNA-clamp PCR.  
 
Supplementary Table 1 
IRCC-Fusion NGS genes panel used to analyze ctDNA 
Description of the IRCC-Fusion panel. (a): list of kinases selected for fusion 
detection and their more frequent partners. (b): list of genes selected for 
mutational analysis.  
 
Supplementary Table 2 
NGS analysis of ctDNA collected before treatment initiation and at 
clinical relapse 
(a) TP53 p.R248W founder mutation and the CAD-ALK rearrangement found 
in the patient’s plasma ctDNA obtained before initiation of entrectinib using 
the IRCC-Fusion Next Generation Sequencing panel.  
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(b) Five activating ALK mutations that emerged in patient’s plasma ctDNA at 
acquired resistance to entrectinib as identified by IRCC-TARGET panel. 
nonsyn: non synonymous;  
 
Supplementary Table 3 
ddPCR raw data of longitudinal analysis of plasma ctDNA 
The table lists the ddPCR events obtained analyzing longitudinal ctDNA 
samples. Each experiment was performed at least in triplicate.  
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Supplementary Table 1
a
b
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5’ Gene Name 5’ Coordinate 3’ Gene Name 3’ Coordinate 
ALK chr2:29447551 CAD chr2:27463267 
CAD chr2:27463262 ALK chr2:29447543 
Cosmic Gene Description Coordinate N change AA change Variant Effect 
% Mutant 
Reads 
641 TP53 Tumor protein p53 chr17:7577539 c.C742T p.R248W nonsyn 7.75 
Cosmic Gene Description Coordinate N change 
AA 
change 
Variant 
Effect 
% Mutant 
Reads 
57 ALK anaplastic lymphoma receptor tyrosine kinase chr2:29443695 c.C3522G p.F1174L nonsyn 1.93237 
14 ALK anaplastic lymphoma receptor tyrosine kinase chr2:29443697 c.T3520C p.F1174L nonsyn 6.08175 
11 ALK anaplastic lymphoma receptor tyrosine kinase chr2:29443696 c.T3521G p.F1174C nonsyn 1.40987 
8 ALK anaplastic lymphoma receptor tyrosine kinase chr2:29436860 c.T3733G p.F1245V nonsyn 1.33753 
1 ALK anaplastic lymphoma receptor tyrosine kinase chr2:29445450 c.G3383C p.G1128A nonsyn 2.83871 
IRCC-Fusion panel – NGS ANALYSIS
ctDNA baseline entrectinib vs reference genome (hg19)
Supplementary T
a
IRCC- TARGET panel – NGS ANALYSIS
ctDNA progression vs cfDNA baseline to entrectinib
b
  
 
Sample Target 
Mutated 
events 
Wild-type  
events 
Fractional 
Abundance(%) 
plasma ctDNA 
24-MAR-2015 
TP53 p.R248W 45 425 9.7 
ALK  p.F1174L (C>G) 0 332 0.0 
ALK  p.F1174L (T>C) 0 366 0.0 
ALK  p.F1174C 0 378 0.0 
ALK  p.G1128A 1 330 0.1 
ALK  p.F1245V 0 331 0.0 
plasma ctDNA 
2-APR-2015 
TP53 p.R248W 0 247 0.0 
ALK  p.F1174L (C>G) 0 183 0.0 
ALK  p.F1174L (T>C) 1 205 0.2 
ALK  p.F1174C 1 213 0.1 
ALK  p.G1128A 0 165 0.0 
ALK  p.F1245V 0 171 0.0 
plasma ctDNA 
24-APR-2015 
TP53 p.R248W 1 186 0.2 
ALK  p.F1174L (C>G) 0 167 0.0 
ALK  p.F1174L (T>C) 0 153 0.0 
ALK  p.F1174C 0 152 0.0 
ALK  p.G1128A 0 129 0.0 
ALK  p.F1245V 0 135 0.0 
plasma ctDNA 
18-MAY-2015 
TP53 p.R248W 1 237 0.4 
ALK  p.F1174L (C>G) 1 206 1.0 
ALK  p.F1174L (T>C) 0 231 0.0 
ALK  p.F1174C 0 188 0.0 
ALK  p.G1128A 0 154 0.0 
ALK  p.F1245V 0 182 0.0 
plasma ctDNA 
13-AUG-2015 
TP53 p.R248W 181 331 35.8 
ALK  p.F1174L (C>G) 19 854 2.1 
ALK  p.F1174L (T>C) 53 935 5.5 
ALK  p.F1174C 17 927 1.9 
ALK  p.G1128A 45 734 5.8 
ALK  p.F1245V 11 762 1.6 
plasma ctDNA 
20-AUG-2015 
TP53 p.R248W 416 1675 20.2 
ALK  p.F1174L (C>G) 32 2528 1.4 
ALK  p.F1174L (T>C) 132 2600 5.3 
ALK  p.F1174C 34 2571 1.4 
ALK  p.G1128A 51 1973 2.7 
ALK  p.F1245V 21 2098 1.1 
plasma ctDNA 
28-AUG-2015 
TP53 p.R248W 831 1187 41.4 
ALK  p.F1174L (C>G) 60 4274 1.5 
ALK  p.F1174L (T>C) 307 4160 7.7 
ALK  p.F1174C 74 4388 1.8 
ALK  p.G1128A 155 3561 4.5 
ALK  p.F1245V 55 3941 1.5 
